Atlas Trials

Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors

Clinical trial NCT04750954 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04750954
Sponsor
National Cancer Institute (NCI)
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Neuroendocrine Neoplasm
Start date
2021-07-22
Primary completion
2026-12-30
Enrollment
29

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.